Cambrex, an East Rutherford, NJ-based contract development and manufacturing organization, acquired Snapdragon Chemistry, a Waltham, Massachusetts-based provider of chemical process development services.
The amount of the deal – expected to close following the completion of customary regulatory approvals – was not disclosed.
With the acquisition, Cambrex will accelerate growth in the area of continuous flow process development and manufacturing, complementing the recent organic investments in its High Point, North Carolina-based facility.
Led by CEO Matt Bio, Snapdragon Chemistry provides chemical process development services to a broad range of emerging and established biopharma customers. It specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing automation technology and proprietary equipment to solve complex process and analytical development challenges. The company has a team of 74 employees. Snapdragon recently opened its second facility, a new 51,000-square-foot facility to manufacture experimental pharmaceutical products for human clinical trials. The new facility expanded the company’s capacity for supplying clinical intermediates and drug substances.
Led by CEO Tom Loewald, Cambrex is a contract development and manufacturing organization (CDMO) that provides drug substance, drug product, and analytical services across the entire drug lifecycle. It offers a range of specialized drug substance technologies and capabilities, including biocatalysis, continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs. In addition, the company can support conventional dosage forms, including oral solids, semi-solids, and liquids, and has the expertise to manufacture specialty dosage forms such as modified-release, fixed-dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile, and non-sterile ointments.